DEMAND FOR DIGNICAP® IS STRONG AS DIGNITANA BRINGS FDA-CLEARED MEDICAL SCALP COOLING DEVICE TO MORE U.S. CANCER CENTERS

Lund, Sweden—June 10, 2016—Dignitana AB, a world leader in medical scalp-cooling technology, announced today that the DigniCap® scalp cooling system, which was recently cleared by the FDA to effectively reduce the likelihood of chemotherapy-induced hair loss in women with breast cancer, is now or will soon be available at 26 cancer treatment centers across the U.S.

The DigniCap® scalp cooling system is the first and only scalp cooling device to complete rigorous FDA clinical trials in the U.S., where seven out of ten patients with early-stage breast cancer kept at least 50% of their hair.

Following FDA Clearance in December 2015, medical centers across the country have begun offering the DigniCap scalp cooling system as part of the comprehensive cancer care treatment services they provide. Through funding from a recent Private Placement and Rights Offering, Dignitana is rapidly expanding its reach across America as demand for the medical device accelerates. Agreements with 26 centers have now been signed*, with some of the early adopters ordering additional units within months of initial set up.

To date, Dignitana has announced installations of the DigniCap® scalp cooling system at the following U.S. medical centers: Bronson Battle Creek Cancer Care Center, Charleston Hematology Oncology Associates, Chesapeake Oncology and Hematology Associates, Florida Cancer Specialists & Research Institute, Menorah Medical Center, Mount Sinai Beth Israel Cancer Center, Mount Sinai Comprehensive Cancer Center, Oncology & Hematology Specialists, Orange County Blood and Cancer Care, The Dubin Breast Center at The Mount Sinai Hospital, Toledo Clinic Cancer Center, Stamford Health Bennett Cancer Center, UCSF Helen Diller Family Comprehensive Cancer Center, UT Health Science Center San Antonio’s Cancer Therapy & Research Center, and Wake Forest Baptist Medical Center.

The following cancer treatment centers are the most recent U.S. sites to include the DigniCap® scalp cooling system as part of their breast cancer treatment care services:

“We are very excited that DigniCap® is being so well-received in the U.S., and that we’ve been able to quickly and effectively fulfil product requests,” said Jan Richardsson, Chief Executive Officer of Dignitana. “From the New York Metropolitan area to communities throughout the midwest, the south, and California, it is clear that DigniCap is filling an important need in quality of life cancer care and medical centers are eagerly promoting its addition to their cancer services.”

The DigniCap® scalp cooling system features a patented tight-fitting silicone cooling cap that is placed directly on the head, and an outer neoprene cap that insulates and secures the silicone cap. The cooling cap is connected to a cooling and control unit with touch screen prompts. A liquid coolant circulates throughout the silicone cap, delivering consistent and controlled cooling to all areas of the scalp. The cap is fitted to the head, and the temperature of the scalp is lowered, resulting in vasoconstriction with reduced delivery of chemotherapy to the scalp, as well as reduced cellular uptake of drugs due to decreased intra follicular metabolic rate. These factors together reduce the risk of chemotherapy-induced hair loss.

För mer info:

Jan Richardsson
VD, Dignitana AB (publ)

Telefon: 046-16 30 92
E-post: jan.richardsson@dignitana.se

Om Dignitana AB (publ)
Dignitanas, med säte i Lund, affärsidé är att utveckla, tillverka och marknadsföra den medicintekniska produkten DigniCap®. Dignitana bedriver en kontinuerlig forskning och utveckling av nya användningsområden för DigniCap®. Dignitanas aktier handlas på NASDAQ OMX First North med Erik Penser Bank som Certified Adviser. För mer information gå in på: www.dignitana.se

Om skalpkylningssystemet DigniCap®
Dignitanas huvudprodukt - skalpkylningssystemet DigniCap® - är ett patenterat system med syfte att eliminera eller kraftigt reducera håravfall för patienter som genomgår cytostatikabehandling. DigniCap® erbjuder skalpkylning med jämn kyla, hög effektivitet, säkerhet och acceptabel komfort.

Taggar:

Om oss

Dignitana AB är världsledande inom kliniskt överlägsen skalpkylningsteknologi. Företaget tillverkar DigniCap® Scalp Cooling System, ett patenterat medicinskt skalpkylningssystem som ger cancerpatienter möjlighet att minimera håravfall under cytostatikabehandling. DigniCap har haft FDA-godkännande sedan 2015 för att ge kontinuerlig skalpkylning med hög effektivitet, säkerhet och patientkomfort. Internationellt uppmärksammad som en livskvalitetshöjande behandling för cancerpatienter, uppfanns DigniCap Scalp Cooling System 1999 av en svensk onkologisjuksköterska och har funnits i Europa sedan 2001. Dignitana AB är noterat på Nasdaq First North Stockholm i Sverige med huvudkontor i Lund, Sverige och verksamhet i Dallas, Texas i USA. Företagets dotterbolag är Dignitana, Inc. i USA och Dignitana S.r.l. i Italien. För mer information: www.dignitana.se och www.dignicap.com.Erik Penser Bank AB är Certified Adviser, +46 (0) 8 463 83 00 certifiedadviser@penser.se www.penser.se

Prenumerera

Citat

We are very excited that DigniCap® is being so well-received in the U.S., and that we’ve been able to quickly and effectively fulfil product requests. From the New York Metropolitan area to communities throughout the midwest, the south, and California, it is clear that DigniCap is filling an important need in quality of life cancer care and medical centers are eagerly promoting its addition to their cancer services.
VD Jan Richardsson Dignitana AB